New York City, NY – According to filings with the U.S. Securities and Exchange Commission, In8bio is raising $34,980,581.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Ho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About In8bio

IN8Bio, Inc. (“IN8bio”) is a biotechnology company advancing an innovative approach towards the treatment of cancers. We are focused on delivering a novel off-the-shelf product for the treatment of cancer. Our unique DRI technology offers an elegant approach to immuno-oncology that deals with multiple mechanisms of tumor resistance and immunosuppression. We believe this approach will lead to the development of more effective treatments for patients with difficult-to-treat solid tumor cancers.

To learn more about In8bio, visit http://www.in8bio.com/

Contact:
William Ho, Chief Executive Officer
646-600-6438
https://www.linkedin.com/in/william-ho-89422b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved